DNA Funded Review 2027Core Trading Conditions and Fees

DNA Funded review 2027: broker-backed challenges with payout limits to understand

DNA Funded launched in late 2024 in partnership with DNA Markets, an Australian broker licensed by ASIC. It is led by Martin Doepke. The firm offers a compact set of challenges on TradeLocker with a wide list of instruments. Its headline terms are competitive. Its payout conditions are more restrictive than they first appear, and they deserve a careful read. This review covers the firm for 2027.

Challenge types

There are five routes. The one-phase challenge, branded Single Helix, has a 10% target with a 6% maximum drawdown. The two-phase challenge, Double Helix, has two targets and a 10% maximum drawdown. The Rapid challenge must be completed within ten days and has a 5% target and a 5% drawdown. Instant Funding has no evaluation. A 24-hour challenge is the newest addition. Account sizes run from $5,000 to $200,000, with prices from $49. The standard challenges have no time limit.

Profit split and boosters

The base split is 80%. A booster bought at checkout raises it to 90%. A second booster shortens the wait for the first payout from 14 days to seven. Each adds roughly a fifth to the price. A third booster allows a reset after failing in the demo stage.

The payout conditions

This is the part to study. On the first three approved payouts, withdrawable profit is capped at 5% of the account. Profit above the cap is removed when the account resets to its starting balance. A 40% rule also applies, limiting how much of the profit can come from a single day. Payouts are subject to a risk review with broad discretion. The minimum withdrawal is $100 after the split. A trader who makes 12% in the first cycle will be paid on 5% of it.

Platform and markets

Trading is on TradeLocker with integrated TradingView charts, and MetaTrader 5 has been added according to some sources. More than 800 instruments are available, including forex, indices, commodities, shares and crypto CFDs. Leverage is modest, up to 1:50 on the two-phase account and 1:30 on others.

Scaling

Traders can hold up to $600,000 in simulated funded capital across accounts.

Broker partnership

The connection to a licensed broker gives the firm access to real liquidity pricing and adds credibility. The prop accounts are simulated and are not covered by the broker's licence.

Reputation

DNA Funded has a small number of public reviews and a middling average score, with some complaints about payouts alongside praise for clear rules and the dashboard. With under two years of operation, trust is still being established.

Things to consider

Limited platform choice will rule the firm out for traders committed to cTrader. The profit cap on early payouts changes the economics for anyone who expects a strong first month. Factor in the cost of boosters when comparing prices.

Choosing a challenge

The two-phase account gives the most drawdown and the highest leverage, and it is the sensible default. The one-phase account is faster with a tighter limit. Rapid and 24-hour challenges reward speed and suit very few strategies.

Pros and cons

• Broker-backed: partnered with an ASIC-licensed broker.
• Instruments: more than 800 symbols.
• Entry price: from $49.
• TradingView charts: built into the platform.
• Payout cap: 5% on the first three payouts.
• Track record: short, with few reviews.

Who is DNA Funded for?

DNA Funded suits traders who like TradeLocker, want a wide instrument list and produce steady, moderate returns that fit within the early payout cap. High-variance traders will lose profit to the cap.

Verdict

DNA Funded has solid backing and fair entry terms. For 2027 the payout conditions are the deciding factor. Model your first three withdrawals before you buy.

DNA Funded review: compare the alternatives

This DNA Funded review is part of our Top 40 Prop Trading Firms in 2027 ranking. To compare, read the Hola Prime review and the Blueberry Funded review.